Cite
HARVARD Citation
Vergnenegre, A. et al. (2016). Economic Analysis of First‐Line Treatment with Erlotinib in anEGFR‐Mutated Population with Advanced NSCLC. Journal of thoracic oncology. 11 (6), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Vergnenegre, A. et al. (2016). Economic Analysis of First‐Line Treatment with Erlotinib in anEGFR‐Mutated Population with Advanced NSCLC. Journal of thoracic oncology. 11 (6), p. . [Online].